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Introduction
Tumor-associated antigens resulting from aberrant glyco-
sylation, such as the Sialyl-Tn carbohydrate antigen, are
over-expressed or exposed on cancer cells and provide
potential targets for cancer vaccination. However, as T-cell
independent antigens carbohydrates are poorly immuno-
genic, and fail to induce memory.
Methods
In order to increase the immunogenicity we have coupled
the Sialyl-Tn carbohydrate antigen to a highly immuno-
genic carrier molecule. The carrier molecule, the mAb17-
1A antibody, provides additional antigens for vaccina-
tion. An immunogenic formulation of mAb17-1A-Sialyl-
Tn conjugate on alhydrogel, IGN402, with or without
additional adjuvants was tested in Rhesus monkeys for
tolerability and immunogenicity.
Results
A significant antibody response against the mAb17-1A
antibody was found by ELISA. Furthermore, also a specific
immune response against the Sialyl-Tn carbohydrate was
induced, and immune sera showed binding reactivity to a
variety of cancer cells.
Conclusion
Immunization in the presence of additional adjuvants,
such as QS-21, strongly enhanced the immune response
against the carbohydrate antigen, and importantly also
resulted in the production of carbohydrate-specific IgG
antibodies. The data indicate that carrier-induced T-cell
help was sufficient for carbohydrate specific class switch
induction.
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